InvestorsHub Logo
Followers 0
Posts 644
Boards Moderated 0
Alias Born 06/16/2014

Re: None

Thursday, 05/05/2016 8:22:19 AM

Thursday, May 05, 2016 8:22:19 AM

Post# of 6939
Eleven Biotherapeutics Reports First Quarter 2016 Financial Results

“We remain on target to make our planned submission of an investigational new drug application for EBI-031 for the treatment of diabetic macular edema this quarter,” said Abbie Celniker, Ph.D., President and Chief Executive Officer of Eleven Biotherapeutics. “In addition, we were pleased to have several opportunities to showcase our data at this week’s ARVO Annual Meeting. We also continue to evaluate strategic alternatives, as previously communicated, with a goal to maximize shareholder value.”

http://finance.yahoo.com/news/eleven-biotherapeutics-reports-first-quarter-113000530.html